Meta-analysis about efficacy of anti-resorptive drugs in post-menopausal osteoporosis

被引:20
作者
Macedo, JMS
Macedo, CRB
Elkis, H
De Oliveira, IR
机构
[1] Univ Fed Bahia, Fac Med, Dept Med, BR-40110100 Salvador, BA, Brazil
[2] Univ Sao Paulo, Inst Psiquiatria, BR-05403010 Sao Paulo, Brazil
关键词
D O I
10.1046/j.1365-2710.1998.00168.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: The purpose of this study was to compare the effect of three groups of anti-resorptive drugs in post-menopausal osteoporosis. Data sources: We collected data covering the period between 1983 and 1995, by first using MEDLINE. References retrieved were scanned further to identify additional papers. Study selection: Only randomized studies evaluating bone mass by means of dual-photon or dual energy densitometry over a period of 1 year were accepted. Data extraction: Studies were arranged into three drug groups. We used densitometry results after 1 year in all treatment or control groups. Factors which might interfere with the results were recorded for subsequent separate analysis. Data synthesis: The MEDLINE search identified almost 25,000 studies. On reading the abstracts, 275 trials appeared to be controlled trials and original copies were retrieved for detailed analysis. A total of 31 articles which satisfied the inclusion criteria were identified. The first meta-analysis included studies which compared oestrogens and placebo, and the global effect-size was 0.54 (95% CI 0.34, 0.73). The second meta-analysis compared calcitonins with placebo and produced an effect-size of 0.41 (95% CI 0.21, 0.61) The third analysis compared bisphosphonates and placebo and showed an effect-size of 0.87 (95% CI 0.68, 1.07). Only oestrogen dose affected the results found. Conclusions: Bisphosphonates had the greatest effect on bone mass in post-menopausal osteoporosis.
引用
收藏
页码:345 / 352
页数:8
相关论文
共 55 条
[1]  
ADAMI S, 1993, OSTEOPOROSIS INT S3, V3, P21
[2]  
ADAMI S, 1989, LANCET, V2, P1469
[3]   CALCITONIN AND ESTROGENS [J].
AGNUSDEI, D ;
CIVITELLI, R ;
CAMPOREALE, A ;
GENNARI, C .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 1990, 13 (08) :625-630
[4]  
[Anonymous], 1989, DSTAT: Software for the meta-analytic review of research literatures
[5]   THE EFFECT OF HIGH-LEVEL PHYSICAL-ACTIVITY (8.5 METS OR GREATER) AND ESTROGEN REPLACEMENT THERAPY UPON BONE MASS IN POSTMENOPAUSAL FEMALES, AGED 50-68 YEARS [J].
BALLARD, JE ;
MCKEOWN, BC ;
GRAHAM, HM ;
ZINKGRAF, SA .
INTERNATIONAL JOURNAL OF SPORTS MEDICINE, 1990, 11 (03) :208-214
[6]  
BARRETTCONNOR E, 1995, AM J MED SA2, V98, P3
[7]   CAN NANDROLONE ADD TO THE EFFECT OF HORMONAL REPLACEMENT THERAPY IN POSTMENOPAUSAL OSTEOPOROSIS [J].
BIRKENHAGER, JC ;
ERDTSIECK, RJ ;
ZEELENBERG, J ;
VANKUIK, C ;
VANVEEN, LCP ;
BIRKENHAGERFRENKEL, DH ;
LUIKEN, GPM ;
KOOY, PPM ;
GERRITSMA, EJ ;
MULDER, P ;
POLS, HAP .
BONE AND MINERAL, 1992, 18 (03) :251-265
[8]  
BURCKHARDT P, 1992, Current Opinion in Rheumatology, V4, P402, DOI 10.1097/00002281-199206000-00020
[9]   BONE-MINERAL DENSITY IN SURGICALLY POSTMENOPAUSAL WOMEN RECEIVING HORMONAL REPLACEMENT THERAPY AS ASSESSED BY DUAL PHOTON-ABSORPTIOMETRY [J].
CASTELOBRANCO, C ;
PONS, F ;
GONZALEZMERLO, J .
MATURITAS, 1993, 16 (02) :133-137
[10]   THE EFFECT OF HORMONE REPLACEMENT THERAPY ON POSTMENOPAUSAL BONE LOSS [J].
CASTELOBRANCO, C ;
DEOSABA, MJM ;
PONS, F ;
GONZALEZMERLO, J .
EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 1992, 44 (02) :131-136